<DOC>
	<DOC>NCT00523601</DOC>
	<brief_summary>To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression</brief_summary>
	<brief_title>Quetiapine Efficacy in Bipolar Depression Study</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent Meet DSMIVTR criteria for bipolar depression at the time of baseline Since this programme intends to describe quetiapine use in routine clinical practice when prescribed as treatment of bipolar depression, there are no programme specific exclusion criteria, other than: Or, any of the following is regarded as a criterion for exclusion from the programme: 1. Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history 2. Known intolerance for or lack of response to quetiapine, as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Bipolar depression</keyword>
	<keyword>quetiapine</keyword>
	<keyword>observational</keyword>
	<keyword>Naturalistic</keyword>
</DOC>